<DOC>
	<DOC>NCT03046459</DOC>
	<brief_summary>This is an open-label, single ascending dose study to characterize the safety and PK/PD profile of IV BNZ132-1-40, a novel peptide inhibitor of multiple cytokines in the IL-2 family.</brief_summary>
	<brief_title>A First-in-Human Study of BNZ132-1-40</brief_title>
	<detailed_description>This is a open-label study of single doses of intravenous BNZ132-1-40 administered to healthy adult subjects. Subjects are followed for 30 days after treatment for collection of safety, PK and PD data. Cohorts of up to 6 subjects will be enrolled for each dose level.</detailed_description>
	<criteria>males and nonpregnant, nonlactating females no ongoing clinically significant medical condition willing and able to provide informed consent no use of Rx or OTC medications, other than oral contraceptives Recent systemic infections Clinicallysignificant abnormal clinical labs, ECG or physical examination Immunization 30 days prior to study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>cytokines</keyword>
	<keyword>interleukin-2</keyword>
	<keyword>Safety Issues</keyword>
</DOC>